703 related articles for article (PubMed ID: 28701395)
41. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.
Chapman R; Shephard E; Stutz H; Douglass N; Sambandamurthy V; Garcia I; Ryffel B; Jacobs W; Williamson AL
PLoS One; 2012; 7(3):e32769. PubMed ID: 22479338
[TBL] [Abstract][Full Text] [Related]
42. Virus-like vaccines against HIV/SIV synergize with a subdominant antigen T cell vaccine.
Schwerdtfeger M; Andersson AC; Neukirch L; Holst PJ
J Transl Med; 2019 May; 17(1):175. PubMed ID: 31126293
[TBL] [Abstract][Full Text] [Related]
43. A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV).
Shen YJ; Shephard E; Douglass N; Johnston N; Adams C; Williamson C; Williamson AL
Virol J; 2011 May; 8():265. PubMed ID: 21624130
[TBL] [Abstract][Full Text] [Related]
44. Enhanced immune response against HIV-1 induced by a heterologous DNA prime-adenovirus boost vaccination using mannosylated polyethyleneimine as DNA vaccine adjuvant.
Li M; Jiang Y; Xu C; Zhang Z; Sun X
Int J Nanomedicine; 2013; 8():1843-54. PubMed ID: 23690682
[TBL] [Abstract][Full Text] [Related]
45. Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.
Liu L; Hao Y; Luo Z; Huang Y; Hu X; Liu Y; Shao Y
Vaccine; 2012 Jun; 30(28):4135-43. PubMed ID: 22561314
[TBL] [Abstract][Full Text] [Related]
46. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.
Sandström E; Nilsson C; Hejdeman B; Bråve A; Bratt G; Robb M; Cox J; Vancott T; Marovich M; Stout R; Aboud S; Bakari M; Pallangyo K; Ljungberg K; Moss B; Earl P; Michael N; Birx D; Mhalu F; Wahren B; Biberfeld G;
J Infect Dis; 2008 Nov; 198(10):1482-90. PubMed ID: 18808335
[TBL] [Abstract][Full Text] [Related]
47. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
[TBL] [Abstract][Full Text] [Related]
48. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
[TBL] [Abstract][Full Text] [Related]
49. Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways.
García-Arriaza J; Arnáez P; Gómez CE; Sorzano CÓ; Esteban M
PLoS One; 2013; 8(6):e66894. PubMed ID: 23826170
[TBL] [Abstract][Full Text] [Related]
50. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
[TBL] [Abstract][Full Text] [Related]
51. Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice.
Andersson AC; Holst PJ
J Transl Med; 2016 Dec; 14(1):343. PubMed ID: 27998269
[TBL] [Abstract][Full Text] [Related]
52. Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers.
Mehendale S; Thakar M; Sahay S; Kumar M; Shete A; Sathyamurthi P; Verma A; Kurle S; Shrotri A; Gilmour J; Goyal R; Dally L; Sayeed E; Zachariah D; Ackland J; Kochhar S; Cox JH; Excler JL; Kumaraswami V; Paranjape R; Ramanathan VD
PLoS One; 2013; 8(2):e55831. PubMed ID: 23418465
[TBL] [Abstract][Full Text] [Related]
53. Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines.
Pillai VK; Kannanganat S; Penaloza-Macmaster P; Chennareddi L; Robinson HL; Blackwell J; Amara RR
Vaccine; 2011 Jul; 29(33):5399-406. PubMed ID: 21651938
[TBL] [Abstract][Full Text] [Related]
54. HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine.
Chege GK; Shephard EG; Meyers A; van Harmelen J; Williamson C; Lynch A; Gray CM; Rybicki EP; Williamson AL
J Gen Virol; 2008 Sep; 89(Pt 9):2214-2227. PubMed ID: 18753231
[TBL] [Abstract][Full Text] [Related]
55. A new multi-clade DNA prime/recombinant MVA boost vaccine induces broad and high levels of HIV-1-specific CD8(+) T-cell and humoral responses in mice.
Bråve A; Boberg A; Gudmundsdotter L; Rollman E; Hallermalm K; Ljungberg K; Blomberg P; Stout R; Paulie S; Sandström E; Biberfeld G; Earl P; Moss B; Cox JH; Wahren B
Mol Ther; 2007 Sep; 15(9):1724-33. PubMed ID: 17579577
[TBL] [Abstract][Full Text] [Related]
56. The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens.
Gómez CE; Nájera JL; Perdiguero B; García-Arriaza J; Sorzano CO; Jiménez V; González-Sanz R; Jiménez JL; Muñoz-Fernández MA; López Bernaldo de Quirós JC; Guardo AC; García F; Gatell JM; Plana M; Esteban M
J Virol; 2011 Nov; 85(21):11468-78. PubMed ID: 21865377
[TBL] [Abstract][Full Text] [Related]
57. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
58. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
[TBL] [Abstract][Full Text] [Related]
59. Prime-boost immunization of codon optimized HIV-1 CRF01_AE Gag in BCG with recombinant vaccinia virus elicits MHC class I and II immune responses in mice.
Promkhatkaew D; Pinyosukhee N; Thongdeejaroen W; Teeka J; Wutthinantiwong P; Leangaramgul P; Sawanpanyalert P; Warachit P
Immunol Invest; 2009; 38(8):762-79. PubMed ID: 19860587
[TBL] [Abstract][Full Text] [Related]
60. A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.
Fournillier A; Frelin L; Jacquier E; Ahlén G; Brass A; Gerossier E; Holmström F; Broderick KE; Sardesai NY; Bonnefoy JY; Inchauspé G; Sällberg M
J Infect Dis; 2013 Sep; 208(6):1008-19. PubMed ID: 23776192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
